Flameret (OTC Pink: FLRE) (PINKSHEETS: FLRE) announced today that it has launched Cannadol™, a hemp oil rich in CBD (cannabidiol) which will be sold in 1 ounce bottles through its wholly-owned subsidiary Royal Hemp Corporation. The product is available immediately online on Royal Hemp’s website (http://www.royalhempcorporation.com) and each bottle of Cannadol ™ includes an organic hemp oil infused with 200mg of CBD. The product also includes about 1/10 of 1% THC (.1%), well beyond the legal threshold for THC content in the United States. The product will be marketed as a hemp oil dietary supplement rich in CBD and will be available for sale throughout the United States. The company is currently restricting sales outside of the United States. The product will be marketed through Royal Hemp Corporation, the company’s recently announced Colorado wholly-owned subsidiary.
Cannabidiol (“CBD”) is one of at least 60 active cannabinoids identified in both cannabis and industrial hemp. It is present in both plants although the prevalence or total composition of CBD can vary greatly from strain to strain.
Unlike THC (the other prevalent cannabinoid), Cannabidiol is non-psychoactive while having the potential to possess a variety of therapeutic properties in many medical conditions including cancer, epilepsy, anxiety, pain and many others. THC and CBD have an inverse relationship, the more CBD, the less THC and the reverse also holds true.
Scientific and clinical studies continue to underscore CBD’s potential (although unproven through scientific studies) as a possible treatment for a wide range of conditions, including rheumatoid arthritis, diabetes, alcoholism, MS, chronic pain, schizophrenia, PTSD, antibiotic-resistant infections, epilepsy, and other neurological disorders. CBD has demonstrated neuroprotective and neurogenic effects, and its anti-cancer properties are currently being investigated at several academic research centers in the United States and elsewhere. However, none of the statements regarding Cannadol™ or the potential therapeutic benefits of cannabidiol have been evaluated by the FDA.
John Meredith, Chief Executive Officer of Flameret, Inc. remarked, “We are thrilled that we can deliver this news to the marketplace. Flameret now has an exciting product available for purchase and we are cautiously optimistic about the commercial potential of Cannadol. We are now one of only a handful of companies in the world selling hemp oil rich in CBD and we will launch our second CBD product by the end of September 2014.”
Mr. Meredith added, “We expect many calls from our shareholders and investors throughout the world asking about sales estimates on Cannadol™. Although we expect significant interest, we will not provide any sales estimates at this time. We will be introducing an additional CBD product to the marketplace in September.”
Flameret, Inc. has developed fire retardant products to suit a wide range of applications. These products are marketed under the brand names; Flameret, Flamex, Ultra Flamex and Impex. Flameret™ products are patented and held in the name of United American Inc.
The company is also in the process of launching a new line of products derived from industrial hemp. These products will be marketed under a wholly-owned subsidiary of Flameret, Inc.
About Royal Hemp Corporation
Royal Hemp Corporation is a Colorado corporation which was created to market and sell hemp based nutraceuticals, industrial products and consumer goods in the United States and throughout the world. All of the corporation’s products will be legal to sell in all states in the United States and in many countries throughout the world.
The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's products, the uncertainty of patent protection for the Company's intellectual property or trade secrets,and the Company's ability to obtain additional financing. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.
SOURCE Flameret, Inc.